Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) has been assigned a $5.00 target price by HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 443.48% from the stock’s current price.
Shares of Ampliphi Biosciences Corp (NYSEAMERICAN APHB) traded down $0.06 during mid-day trading on Wednesday, reaching $0.92. The company’s stock had a trading volume of 236,600 shares, compared to its average volume of 483,975. Ampliphi Biosciences Corp has a 52-week low of $0.67 and a 52-week high of $7.50.
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.02. Ampliphi Biosciences Corp had a negative return on equity of 313.95% and a negative net margin of 23,075.00%. The company had revenue of $0.03 million for the quarter.
Ampliphi Biosciences Corp Company Profile
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.
Receive News & Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.